NICE approve ibrutinib in the UK

John Gribben, MD, DSc, FRCPath, FMed Sci from Bart's Cancer Institute, London, UK provides patients with an update on chronic lymphocytic leukemia (CLL) treatments following the recent approval of ibrutinib in the UK by NICE. Prof. Gribben talks about the 3 agents currently available to treat CLL: idelalisib, ibrutinib and venetoclax, and the benefits of having these agents available for treating CLL patients. Prof. Gribben explains the importance of clinical trials and the cost benefits of trialing combination therapies in CLL. Last, he comments on the shift from chemo-immunotherapy towards new targeted therapies, highlighting the importance of patients continuing to enroll in clinical trials. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Видео NICE approve ibrutinib in the UK канала Patient Power Europe